Penny Nymark

List of Publications by Citations

42 papers	**1,120** citations	**21** h-index	**33** g-index
59 ext. papers	**1,365** ext. citations	**6.6** avg, IF	**3.99** L-index

#	Paper	IF	Citations
42	Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. *Genes Chromosomes and Cancer*, **2011**, 50, 585-97	5	103
41	Genotoxicity of polyvinylpyrrolidone-coated silver nanoparticles in BEAS 2B cells. *Toxicology*, **2013**, 313, 38-48	4.4	85
40	CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. *Genes Chromosomes and Cancer*, **2005**, 42, 193-9	5	70
39	Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. *Particle and Fibre Toxicology*, **2020**, 17, 16	8.4	68
38	Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. *BMC Genomics*, **2007**, 8, 62	4.5	60
37	Identification of specific gene copy number changes in asbestos-related lung cancer. *Cancer Research*, **2006**, 66, 5737-43	10.1	52
36	In vitro and in vivo genotoxic effects of straight versus tangled multi-walled carbon nanotubes. *Nanotoxicology*, **2016**, 10, 794-806	5.3	47
35	A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions. *Toxicological Sciences*, **2018**, 162, 264-275	4.4	43
34	Free radical scavenging and formation by multi-walled carbon nanotubes in cell free conditions and in human bronchial epithelial cells. *Particle and Fibre Toxicology*, **2014**, 11, 4	8.4	43
33	Molecular and genetic changes in asbestos-related lung cancer. *Cancer Letters*, **2008**, 265, 1-15	9.9	43
32	NanoSolveIT Project: Driving nanoinformatics research to develop innovative and integrated tools for nanosafety assessment. *Computational and Structural Biotechnology Journal*, **2020**, 18, 583-602	6.8	41
31	Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. *Oncogene*, **2007**, 26, 4730-7	9.2	40
30	Nanomaterial grouping: Existing approaches and future recommendations. *NanoImpact*, **2019**, 16, 100182	3.6	32
29	Safe innovation approach: Towards an agile system for dealing with innovations. *Materials Today Communications*, **2019**, 20, 100548	2.5	32
28	Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. *Carcinogenesis*, **2008**, 29, 913-7	4.6	28
27	Toward the Replacement of Animal Experiments through the Bioinformatics-driven Analysis of \Omics\Data from Human Cell Cultures. *ATLA Alternatives To Laboratory Animals*, **2015**, 43, 325-32	2.1	27
26	DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure. *British Journal of Cancer*, **2009**, 100, 1336-42	8.7	26

25	Extensive temporal transcriptome and microRNA analyses identify molecular mechanisms underlying mitochondrial dysfunction induced by multi-walled carbon nanotubes in human lung cells. *Nanotoxicology*, **2015**, 9, 624-35	5.3	24
24	Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices. *Small*, **2020**, 16, e1904749	11	24
23	Towards FAIR nanosafety data. *Nature Nanotechnology*, **2021**, 16, 644-654	28.7	23
22	Insights into possibilities for grouping and read-across for nanomaterials in EU chemicals legislation. *Nanotoxicology*, **2019**, 13, 119-141	5.3	21
21	Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials. *Frontiers in Genetics*, **2018**, 9, 661	4.5	20
20	Transcriptomics in Toxicogenomics, Part III: Data Modelling for Risk Assessment. *Nanomaterials*, **2020**, 10,	5.4	19
19	Transcriptomics in Toxicogenomics, Part I: Experimental Design, Technologies, Publicly Available Data, and Regulatory Aspects. *Nanomaterials*, **2020**, 10,	5.4	18
18	Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. *Molecular Oncology*, **2013**, 7, 29-40	7.9	18
17	Molecular alterations at 9q33.1 and polyploidy in asbestos-related lung cancer. *Clinical Cancer Research*, **2009**, 15, 468-75	12.9	18
16	Transcriptomics in Toxicogenomics, Part II: Preprocessing and Differential Expression Analysis for High Quality Data. *Nanomaterials*, **2020**, 10,	5.4	16
15	Toxic and Genomic Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse Outcome. *Annals of the American Thoracic Society*, **2018**, 15, S91-S97	4.7	16
14	toxFlow: A Web-Based Application for Read-Across Toxicity Prediction Using Omics and Physicochemical Data. *Journal of Chemical Information and Modeling*, **2018**, 58, 543-549	6.1	15
13	Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints. *Small*, **2021**, 17, e2007628	11	11
12	Enriching Nanomaterials Omics Data: An Integration Technique to Generate Biological Descriptors. *Small Methods*, **2017**, 1, 1700139	12.8	9
11	In Vitro Three-Dimensional Liver Models for Nanomaterial DNA Damage Assessment. *Small*, **2021**, 17, e2006055	11	8
10	Adverse Outcome Pathway Development for Assessment of Lung Carcinogenicity by Nanoparticles.. *Frontiers in Toxicology*, **2021**, 3, 653386	1.6	6
9	Reliable Surface Analysis Data of Nanomaterials in Support of Risk Assessment Based on Minimum Information Requirements. *Nanomaterials*, **2021**, 11,	5.4	3
8	Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework. *Frontiers in Public Health*, **2021**, 9, 638605	6	3

7	FAIRification of nanosafety data to improve applicability of (Q)SAR approaches: A case study on Comet assay genotoxicity data. *Computational Toxicology*, **2021**, 20, 100190	3.1	1
6	Reply to: Prospects and challenges for FAIR toxicogenomics data.. *Nature Nanotechnology*, **2021**,	28.7	1
5	ELIXIR and Toxicology: a community in development. *F1000Research*, **2021**, 10, 1129	3.6	0
4	A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma.. *Frontiers in Oncology*, **2022**, 12, 849640	5.3	0
3	Tumors of the Lung **2010**, 415-428		
2	Lung Cancer: Molecular Markers of Occupational Carcinogens **2020**, 227-238		
1	Tumors of the lung361-372		